Seattle Genetics Inc. (SGEN) Reports In-Line Q2 EPS

Seattle Genetics Inc. (NASDAQ: SGEN) reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $50.33 million.

For earnings history and earnings-related data on Seattle Genetics Inc. (SGEN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
• Onto Innovation gains on bullish RBC initiation citing advanced packaging growth